Showing results (11-20 of 130) with videos related to
Sort By:
Pageof 13
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 7, 2022
The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database AnalysisKristina S Boye, Maureen J Lage, Vivian T ThieuDiabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 23, 2023
Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 DiabetesKristina S Boye, Katie D Stewart, Louis S MatzaExpert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006)Lizheng Shi, Meredith Hodges, Nicole Yurgin, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literatureSusan L Dennett, Kristina S Boye, Nicole R YurginHealth and Quality of Life Outcomes|June 14, 2017
Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studiesShuichi Suzuki, Tomonori Oura, Masakazu Takeuchi, et al.Applied Health Economics and Health Policy|November 13, 2009
A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargineDerek Misurski, Maureen J Lage, Rosalind Fabunmi, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 28, 2019
GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims DataVictoria Divino, Kristina S Boye, Jeremie Lebrec, et al.Patient Preference and Adherence|August 12, 2022
Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking BehaviorsTracy J Sims, Kristina S Boye, Susan Robinson, et al.Advances in Therapy|February 17, 2009
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapyMaureen J Lage, Rosalind Fabunmi, Kristina S Boye, et al.Clinical Therapeutics|August 4, 2020
The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 DiabetesKristina S Boye, Reema Mody, Maureen J Lage, et al.Pageof 13